Portage Biotech Inc. (PRTG)

Name: Portage Biotech Inc. (PRTG) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Portage Biotech Inc. (PRTG)

Stock Card

$4.70

$-0.47 (-9.09%)

As on 05-Nov-2025 09:30EDT

Market cap

$16 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

9.3

Div. Yield

0 %

Value Research Rating

Quality Score

Growth Score

Valuation Score

Momentum Score

Know more

Explore 5 star rated stocks

Portage Biotech (PRTG) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 4.32 High: 4.90

52 Week Range

Low: 2.95 High: 15.82

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-5.4 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-0
Debt to Equity

--
Book Value

$--
EPS

$-6.3
Face value

--
Shares outstanding

2,278,620

10 Years Aggregate

CFO

$-40.48 Mln

EBITDA

$7.02 Mln

Net Profit

$-25.94 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Portage Biotech (PRTG)	-9.1	-21.0	-19.9	-6.2	-67.5	-51.8	-23.5
BSE Sensex^*	-9.1	-1.5	2.9	-3.6	5.9	6.0	10.5
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 05-Nov-2025 | *As on 01-Sep-2026 | #As on 26-Oct-2023

Company	2023	2022
Portage Biotech (PRTG)	-65.6	-50.7
S&P Small-Cap 600	13.9	-17.4
BSE Sensex	18.7	4.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Portage Biotech (PRTG)	4.7	15.5	0.0	-6.8	--	-347.1	--	9.3
Biohaven Pharmaceutical Holding Co (BHVN)	15.3	2,092.0	0.0	-586.8	--	-1825.5	--	166.8

Shareholding Pattern

View Details

About Portage Biotech (PRTG)

Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline comprises PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1... positive tumors; PORT-6, a highly selective A2A receptor antagonist, which is in phase 1a for the treatment of solid tumors; PORT-8, a dual inhibitor of adenosine receptors 2A and 2B, which is in preclinical trial to treat solid tumors; PORT-9, an A2B antagonist, which is in pre-clinical stage program to treat colorectal and gastrointestinal cancers; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; PORT-5, a VLP-STING to treat of solid tumors and is in preclinical trials; and PORT-7, a potent and selective antagonist of the adenosine A2B receptor. Portage Biotech Inc. is based in Tortola, British Virgin Islands. Read more

CEO & Chairman of Board

Dr. Ian B. Walters M.B.A., M.D.
CEO & Chairman of Board

Dr. Ian B. Walters M.B.A., M.D.
Headquarters

Tortola
Website

https://www.portagebiotech.com

FAQs for Portage Biotech (PRTG)

What is the current share price of Portage Biotech Inc (PRTG) Today?

The share price of Portage Biotech Inc (PRTG) is $4.70 (NASDAQ) as of 05-Nov-2025 09:30 EDT. Portage Biotech Inc (PRTG) has given a return of -67.49% in the last 3 years.

What is the current PB & PE ratio of Portage Biotech Inc (PRTG)?

Since, TTM earnings of Portage Biotech Inc (PRTG) is negative, P/E ratio is not available.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2025	-1.47	-80.92
2024	-0.01	0.14
2023	-0.52	0.72
2022	-5.20	0.72
2021	-21.25	3.32

What is the 52 Week High and Low of Portage Biotech Inc (PRTG)?

The 52-week high and low of Portage Biotech Inc (PRTG) are Rs 15.82 and Rs 2.95 as of 01-Sep-2026.

What is the market cap of Portage Biotech Inc (PRTG)?

Portage Biotech Inc (PRTG) has a market capitalisation of $ 16 Mln as on 05-Nov-2025. As per SEBI classification, it is a Small Cap company.

Should I invest in Portage Biotech Inc (PRTG)?

Before investing in Portage Biotech Inc (PRTG), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.